Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells

Journal of Immunology

Volumn 191, Issue 8, 2013, Pages 4141-4151

  Lee Chang, Catalina ^a   Bodogai, Monica ^a   Martin Montalvo, Alejandro ^a   Wejksza, Katarzyna ^a   Sanghvi, Mitesh ^a   Moaddel, Ruin ^a   De Cabo, Rafael ^a   Biragyn, Arya ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RESVERATROL; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; FEMALE; LOW DRUG DOSE; LUNG METASTASIS; MELANOMA; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; TUMOR ESCAPE; TUMOR EVOKED REGULATORY B CELL;

ANIMALS; B-LYMPHOCYTES, REGULATORY; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; STAT3 TRANSCRIPTION FACTOR; STILBENES; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84885451683     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300606     Document Type: Article

References (53)

1. Lelekakis, M., J. M. Moseley, T. J. Martin, D. Hards, E. Williams, P. Ho, D. Lowen, J. Javni, F. R. Miller, J. Slavin, and R. L. Anderson. 1999. A novel orthotopic model of breast cancer metastasis to bone. Clin. Exp. Metastasis 17: 163-170.
2. Sinha, P., V. K. Clements, and S. Ostrand-Rosenberg. 2005. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 174: 636-645.
3. Youn, J. I., S. Nagaraj, M. Collazo, and D. I. Gabrilovich. 2008. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181: 5791-5802.
4. Bunt, S. K., P. Sinha, V. K. Clements, J. Leips, and S. Ostrand-Rosenberg. 2006. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 176: 284-290.
5. Pan, P. Y., G. Ma, K. J. Weber, J. Ozao-Choy, G. Wang, B. Yin, C. M. Divino, and S. H. Chen. 2010. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 70: 99-108.
6. Walker, M. R., B. D. Carson, G. T. Nepom, S. F. Ziegler, and J. H. Buckner. 2005. De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD252 cells. Proc. Natl. Acad. Sci. USA 102: 4103-4108.
7. Ramos, R. N., L. S. Chin, A. P. Dos Santos, P. C. Bergami-Santos, F. Laginha, and J. A. Barbuto. 2012. Monocyte-derived dendritic cells from breast cancer patients are biased to induce CD4+CD25+Foxp3+ regulatory T cells. J. Leukoc. Biol. 92: 673-682.
8. Woo, E. Y., H. Yeh, C. S. Chu, K. Schlienger, R. G. Carroll, J. L. Riley, L. R. Kaiser, and C. H. June. 2002. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168: 4272-4276.
9. Beyer, M., M. Kochanek, K. Darabi, A. Popov, M. Jensen, E. Endl, P. A. Knolle, R. K. Thomas, M. von Bergwelt-Baildon, S. Debey, et al. 2005. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106: 2018-2025.
10. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949.
11. Olkhanud, P. B., D. Baatar, M. Bodogai, F. Hakim, R. Gress, R. L. Anderson, J. Deng, M. Xu, S. Briest, and A. Biragyn. 2009. Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res. 69: 5996-6004.
12. Olkhanud, P. B., Y. Rochman, M. Bodogai, E. Malchinkhuu, K. Wejksza, M. Xu, R. E. Gress, C. Hesdorffer, W. J. Leonard, and A. Biragyn. 2011. Thymic stromal lymphopoietin is a key mediator of breast cancer progression. J. Immunol. 186: 5656-5662.
13. Olkhanud, P. B., B. Damdinsuren, M. Bodogai, R. E. Gress, R. Sen, K. Wejksza, E. Malchinkhuu, R. P. Wersto, and A. Biragyn. 2011. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells. Cancer Res. 71: 3505-3515.
14. Bodogai, M., C. Lee-Chang, K. Wejksza, J. P. Lai, M. Merino, R. P. Wersto, R. E. Gress, A. C. Chan, C. Hesdorffer, and A. Biragyn. 2013. Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. Cancer Res. 73: 2127-2138.
15. Wejksza, K., C. Lee-Chang, B. Bodogai, B. Bonzo, F. J. Gonzalez, E. Lehrmann, K. Becker, and A. Biragyn. 2013. Cancer-produced metabolites of 5-lipoxygenase induce tumor-evoked regulatory B cells via peroxisome proliferatoractivated receptor a. J. Immunol. 190: 2575-2584.
16. Ding, Q., M. Yeung, G. Camirand, Q. Zeng, H. Akiba, H. Yagita, G. Chalasani, M. H. Sayegh, N. Najafian, and D. M. Rothstein. 2011. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J. Clin. Invest. 121: 3645-3656.
17. Byrne, S. N., and G. M. Halliday. 2005. B cells activated in lymph nodes in response to ultraviolet irradiation or by interleukin-10 inhibit dendritic cell induction of immunity. J. Invest. Dermatol. 124: 570-578.
18. Sun, J. B., C. F. Flach, C. Czerkinsky, and J. Holmgren. 2008. B lymphocytes promote expansion of regulatory T cells in oral tolerance: powerful induction by antigen coupled to cholera toxin B subunit. J. Immunol. 181: 8278-8287.
19. de Visser, K. E., L. V. Korets, and L. M. Coussens. 2005. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7: 411-423.
20. Ammirante, M., J. L. Luo, S. Grivennikov, S. Nedospasov, and M. Karin. 2010. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464: 302-305.
21. Qin, Z., G. Richter, T. Schüler, S. Ibe, X. Cao, and T. Blankenstein. 1998. B cells inhibit induction of T cell-dependent tumor immunity. Nat. Med. 4: 627-630.
22. Lindner, S., K. Dahlke, K. Sontheimer, M. Hagn, C. Kaltenmeier, T. F. Barth, T. Beyer, F. Reister, D. Fabricius, R. Lotfi, et al. 2013. Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. Cancer Res. 73: 2468-2479.
23. Sorrentino, R., S. Morello, G. Forte, A. Montinaro, G. De Vita, A. Luciano, G. Palma, C. Arra, P. Maiolino, I. M. Adcock, and A. Pinto. 2011. B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma. Am. J. Respir. Crit. Care Med. 183: 1369-1379.
24. Aklilu, M., W. M. Stadler, M. Markiewicz, N. J. Vogelzang, M. Mahowald, M. Johnson, and T. F. Gajewski. 2004. Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann. Oncol. 15: 1109-1114.
25. Athar, M., J. H. Back, L. Kopelovich, D. R. Bickers, and A. L. Kim. 2009. Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch. Biochem. Biophys. 486: 95-102.
26. Bhat, K. P., D. Lantvit, K. Christov, R. G. Mehta, R. C. Moon, and J. M. Pezzuto. 2001. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res. 61: 7456-7463.
27. Jang, M., L. Cai, G. O. Udeani, K. V. Slowing, C. F. Thomas, C. W. Beecher, H. H. Fong, N. R. Farnsworth, A. D. Kinghorn, R. G. Mehta, et al. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220.
28. Jeong, M. H., K. M. Yang, Y. J. Choi, S. D. Kim, Y. H. Yoo, S. Y. Seo, S. H. Lee, S. R. Ryu, C. M. Lee, Hs. Suh, and W. S. Jo. 2012. Resveratrol analog, HS-1793 enhance anti-tumor immunity by reducing the CD4+CD25+ regulatory T cells in FM3A tumor bearing mice. Int. Immunopharmacol. 14: 328-333.
29. Guan, H., N. P. Singh, U. P. Singh, P. S. Nagarkatti, and M. Nagarkatti. 2012. Resveratrol prevents endothelial cells injury in high-dose interleukin-2 therapy against melanoma. PLoS ONE 7: e35650.
30. Bove, K., D. W. Lincoln, and M. F. Tsan. 2002. Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem. Biophys. Res. Commun. 291: 1001-1005.
31. Klink, J. C., A. K. Tewari, E. M. Masko, J. Antonelli, P. G. Febbo, P. Cohen, M. W. Dewhirst, S. V. Pizzo, and S. J. Freedland. 2013. Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways. Prostate 73: 754-762.
32. Popat, R., T. Plesner, F. Davies, G. Cook, M. Cook, P. Elliott, E. Jacobson, T. Gumbleton, H. Oakervee, and J. Cavenagh. 2013. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Br. J. Haematol. 160: 714-717.
33. Tiwari, V., and K. Chopra. 2011. Resveratrol prevents alcohol-induced cognitive deficits and brain damage by blocking inflammatory signaling and cell death cascade in neonatal rat brain. J. Neurochem. 117: 678-690.
34. Rahal, K., P. Schmiedlin-Ren, J. Adler, M. Dhanani, V. Sultani, A. C. Rittershaus, L. Reingold, J. Zhu, B. J. McKenna, G. M. Christman, and E. M. Zimmermann. 2012. Resveratrol has antiinflammatory and antifibrotic effects in the peptidoglycan-polysaccharide rat model of Crohn's disease. Inflamm. Bowel Dis. 18: 613-623.
35. Suenaga, F., K. Hatsushika, S. Takano, T. Ando, Y. Ohnuma, H. Ogawa, and A. Nakao. 2008. A possible link between resveratrol and TGF-beta: resveratrol induction of TGF-beta expression and signaling. FEBS Lett. 582: 586-590.
36. Serrero, G., and R. Lu. 2001. Effect of resveratrol on the expression of autocrine growth modulators in human breast cancer cells. Antioxid. Redox Signal. 3: 969-979.
37. Yang, Y., J. H. Paik, D. Cho, J. A. Cho, and C. W. Kim. 2008. Resveratrol induces the suppression of tumor-derived CD4+CD25+ regulatory T cells. Int. Immunopharmacol. 8: 542-547.
38. Bhardwaj, A., G. Sethi, S. Vadhan-Raj, C. Bueso-Ramos, Y. Takada, U. Gaur, A. S. Nair, S. Shishodia, and B. B. Aggarwal. 2007. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through downregulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 109: 2293-2302.
39. Lee, H., P. Zhang, A. Herrmann, C. Yang, H. Xin, Z. Wang, D. S. Hoon, S. J. Forman, R. Jove, A. D. Riggs, and H. Yu. 2012. Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc. Natl. Acad. Sci. USA 109: 7765-7769.
40. Kotha, A., M. Sekharam, L. Cilenti, K. Siddiquee, A. Khaled, A. S. Zervos, B. Carter, J. Turkson, and R. Jove. 2006. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol. Cancer Ther. 5: 621-629.
41. Overwijk, W. W., M. R. Theoret, S. E. Finkelstein, D. R. Surman, L. A. de Jong, F. A. Vyth-Dreese, T. A. Dellemijn, P. A. Antony, P. J. Spiess, D. C. Palmer, et al. 2003. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198: 569-580.
42. Boocock, D. J., K. R. Patel, G. E. Faust, D. P. Normolle, T. H. Marczylo, J. A. Crowell, D. E. Brenner, T. D. Booth, A. Gescher, and W. P. Steward. 2007. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 848: 182-187.
43. Pandey, P. R., F. Xing, S. Sharma, M. Watabe, S. K. Pai, M. Iiizumi-Gairani, K. Fukuda, S. Hirota, Y. Y. Mo, and K. Watabe. 2012. Elevated lipogenesis in epithelial stem-like cell confers survival advantage in ductal carcinoma in situ of breast cancer. Oncogene. DOI: 10.1038/onc.2012.519.
44. Walle, T., F. Hsieh, M. H. DeLegge, J. E. Oatis, Jr., and U. K. Walle. 2004. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 32: 1377-1382.
45. Poulsen, M. M., P. F. Vestergaard, B. F. Clasen, Y. Radko, L. P. Christensen H. Stodkilde-Jorgensen, N. Moller, N. Jessen, S. B. Pedersen, and J. O. Jorgensen. 2012. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 62: 1186-1195.
46. Ferrer, P., M. Asensi, R. Segarra, A. Ortega, M. Benlloch, E. Obrador, M. T. Varea, G. Asensio, L. Jordá, and J. M. Estrela. 2005. Association between pterostilbene and quercetin inhibits metastatic activity of B16 melanoma. Neoplasia 7: 37-47.
47. Hawley, S. A., F. A. Ross, C. Chevtzoff, K. A. Green, A. Evans, S. Fogarty, M. C. Towler, L. J. Brown, O. A. Ogunbayo, A. M. Evans, and D. G. Hardie. 2010. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 11: 554-565.
48. Dasgupta, B., and J. Milbrandt. 2007. Resveratrol stimulates AMP kinase activity in neurons. Proc. Natl. Acad. Sci. USA 104: 7217-7222.
49. Crowell, J. A., P. J. Korytko, R. L. Morrissey, T. D. Booth, and B. S. Levine. 2004. Resveratrol-Associated renal toxicity. Toxicol. Sci. 82: 614-619.
50. Serafini, P., S. Mgebroff, K. Noonan, and I. Borrello. 2008. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68: 5439-5449.
51. Serafini, P., C. De Santo, I. Marigo, S. Cingarlini, L. Dolcetti, G. Gallina, P. Zanovello, and V. Bronte. 2004. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 53: 64-72.
52. Nagaraj, S., and D. I. Gabrilovich. 2008. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 68: 2561-2563.
53. Ogata, H., T. Chinen, T. Yoshida, I. Kinjyo, G. Takaesu, H. Shiraishi, M. Iida, T. Kobayashi, and A. Yoshimura. 2006. Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta1 production. Oncogene 25: 2520-2530.